NLSP (NLS Pharmaceutics) חוב לטווח קצר להון

NLS Pharmaceutics AG (NLSP) optimizes production by relying on external CMO laboratories in the US and Switzerland, ensuring supply chain reliability. The firm's financial status depends exclusively on the testing phases of new drugs and regulatory verdicts, ignoring general market cycles. The price action vector available for analysis on GURU.Markets, where the indicator is 0.00, illustrates a business focused on developing medications for ADHD and insomnia.

This indicator measures the ratio of short-term liabilities to equity, determining the dependence of liquidity on external borrowings with a maturity of up to one year. For NLS Pharmaceutics AG (NLSP), which invests in the development of treatments for ADHD and narcolepsy, the trend of short-term loans relative to equity reflects the balance between financial stability and the costs of expansion into neurobiology, confirming the quality of capital management.